REDWOOD CITY, Calif., March 18 /PRNewswire/ -- Ingenuity Systems, the leading provider of information solutions for life science researchers, has announced that they have extended and expanded their existing license agreement with GlaxoSmithKline for access to Ingenuity Pathways Analysis (IPA) software. The new agreement enables GSK to provide enterprise-wide IPA access to researchers for rapid assessment of the signaling and metabolic pathways, molecular networks, and biological processes that are most significant to disease targets. In addition, GSK will also use Ingenuity's content and proprietary algorithms.
"We are very pleased that GSK will now be able to leverage IPA and other Ingenuity information solutions at the enterprise level," stated Jake Leschly, CEO, Ingenuity Systems. "Many discovery programs at GSK have already successfully used IPA to understand the complex relationship between pathways and disease. Research teams across the organization will now be able to use these insights to make effective decisions as to which drug targets and compounds to pursue."
About Ingenuity Pathways Analysis
Ingenuity Pathways Analysis is an all-in-one software application that enables researchers to model, analyze, and understand the complex biological and chemical systems at the core of life science research. IPA's search capabilities provide users with access to the highest quality detail-rich knowledge available on genes, drugs, chemicals, protein families, cellular and disease processes, and signaling and metabolic pathways. IPA supports analysis of data from all experimental platforms, and is used at all stages of the drug discovery and development process, including target identification and validation, biomarker discovery, molecular toxicology, metabolomics, and pharmacogenomics. IPA has been broadly adopted and cited in hundreds of peer-reviewed journals.
About Ingenuity Systems(R)
Ingenuity Systems is a leading provider of information solutions for the exploration, interpretation, and analysis of life science information. All of Ingenuity's products and services have one common goal -- to help life science researchers generate maximum value from all types of biological and chemical knowledge. Ingenuity offers a broad and flexible range of solutions that can be tailored to needs of various clients, including academic and therapeutic area researchers, computational biologists and informatics departments, and suppliers in the life sciences industry. All of the products leverage Ingenuity's knowledge base, the largest data base of its kind, which houses the biological and chemical relationships extracted from scientific literature. The information is uniquely structured so scientists can ask complex biological questions to gain rapid insight into their experimental data or create relevant biological models to move forward in their research. Today, Ingenuity's solutions are used by thousands of researchers at hundreds of leading pharmaceutical, biotechnology, and academic research institutions worldwide. Ingenuity was founded in 1998 and is headquartered in Redwood City, California with offices in Germany, Switzerland, France, the United Kingdom, Australia, and Japan. http://www.ingenuity.com.
SOURCE Ingenuity Systems(R)
